Join the Mounjaro group to help and get support from people like you.
Mounjaro News
Mounjaro, Zepbound Cut Odds for Diabetes by 94% in At-Risk People, Study Finds
TUESDAY, Aug. 20, 2024 – Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes...
Mounjaro, Zepbound Cut Odds for Diabetes by 94% in At-Risk People, Study Finds
TUESDAY, Aug. 20, 2024 – Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes...
Risks for Mortality, Adverse Heart, Kidney Events Lower With Tirzepatide for T2DM
MONDAY, Aug. 12, 2024 – For patients with type 2 diabetes, treatment with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist) is associated...
GLP-1 RAs May Reduce Risk for Some Obesity-Linked Cancers Versus Insulin in T2D
THURSDAY, July 11, 2024 – For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers...
Significantly More Weight Loss Seen With Tirzepatide Versus Semaglutide
MONDAY, July 8, 2024 – Tirzepatide is associated with significantly greater weight loss than semaglutide for adults with overweight or obesity, according to a study published online July 8 in JAMA...
Mounjaro Bests Ozempic for Weight Loss
MONDAY, July 8, 2024 – Mounjaro outperforms Ozempic in helping people lose weight, a new study shows. People taking tirzepatide (Mounjaro, Zepbound) dropped significantly more pounds than those...
ADA: Tirzepatide Reduces Apnea-Hypopnea Index in Moderate-to-Severe OSA
WEDNESDAY, June 26, 2024 – Tirzepatide reduces the apnea-hypopnea index (AHI) among individuals with moderate-to-severe obstructive sleep apnea and obesity, according to a study published online...
GLP-1 Medicine Mounjaro May Be First Drug to Ease Sleep Apnea
FRIDAY, June 21, 2024 – A medication used to manage type 2 diabetes has been found effective in treating sleep apnea. The worldwide clinical trial demonstrates that tirzepatide significantly lowers...
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
THURSDAY, June 13, 2024 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective than placebo for...
Most Slow Responders to Tirzepatide Do Lose Clinically Meaningful Weight
TUESDAY, May 14, 2024 – Among slow responders to tirzepatide treatment at week 12, 90 percent went on to achieve clinically meaningful weight reduction (≥5 percent) by week 72, according to a study p...
Aspiration Pneumonia Risk Increased for GLP-1 RA Users Undergoing Endoscopy
FRIDAY, April 12, 2024 – Patients using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) undergoing endoscopic procedures have an increased risk for aspiration pneumonia, according to a study...
Tirzepatide Improves 24-Hour BP in Obesity-Related Hypertension
WEDNESDAY, Feb. 7, 2024 – For patients with obesity and hypertension, tirzepatide improves 24-hour blood pressure (BP), according to a research letter published online Feb. 5 in Hypertension. James...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
Continuing Tirzepatide Leads to Maintenance of Weight Reduction
MONDAY, Dec. 11, 2023 – Withdrawing tirzepatide after 36 weeks is associated with regain of lost weight, while weight loss is maintained with continued treatment, according to a study published...
Half of Diabetes Patients on Ozempic, Mounjaro Stop Using the Meds
TUESDAY, Dec. 12, 2023 – Many Americans battling diabetes are turning to a new class of injected drugs that includes blockbusters like Ozempic (semaglutide) and Mounjaro (tirzepatide). But a new...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Diabetes, Type 2